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Abstract (200 words max): 
 
Purpose of review:   
Marginal donor kidneys make up a substantial proportion of transplanted kidneys.  
Nonetheless, they are more susceptible to injury during procurement and preservation.  
Normothermic perfusion is an alternative method of organ preservation that can be 
used to improve the quality/resuscitate, assess and potentially repair the organ. This 
review provides an up to date summary of the role of ex-vivo normothermic perfusion 
(EVNP) in renal transplantation and what we can expect in the future. 
 
Recent findings:   
EVNP has been demonstrated to be a feasible and safe method of organ preservation 
in series of extended criteria donor kidneys (ECD).  Furthermore, EVNP can be used 
as a quality assessment tool for kidneys pre-transplant. In the future, EVNP could be 
used to manipulate the organ using gene and stem  ameliorating renal function after 
injury. 
 
Summary: 
In the last 5 years EVNP has been translated from an experimental laboratory 
technique into clinical practice with promising results.  EVNP has demonstrated itself 
to be multi-faceted in its application in renal transplantation, offering an improved 
preservation technique, particularly for marginal donor kidneys and real-time quality 
assessment of the kidney pre-transplant.  The implications of these applications are 
crucial in maximizing the use of donor organs available in the perpetual climate of 
organ shortage. 
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Introduction 
Ex-vivo normothermic perfusion (EVNP) in kidney transplantation is a promising 
area of research that has seen translation from experimental models into early clinical 
practice.  The potential applications of EVNP are multi-fold; from optimising organ 
preservation techniques, particularly apt in the climate of an increasingly used pool of 
marginal donor organs, to real-time quality assessment of donor organs. It also 
provides an ideal platform for targeted therapies such as gene and stem cell therapies.  
This review provides an update on EVNP within renal transplantation and the 
progression to date.  It will also focus on what can be expected for the future of 
EVNP in kidney transplantation drawing upon research from other transplantation 
fields. 
 
History of EVNP 
Although experimental normothermic perfusion techniques were first introduced in 
the early twentieth century by the French surgeon and scientist Alexis Carrel (1-5), 
isolated organ perfusion at normothermic temperatures ex-vivo gained momentum 
only in the last few decades.   This has been fuelled by technology, such as 
extracorporeal membrane oxygenators, cardiopulmonary bypass systems (6-7) and the 
shortage of organ donors. A great deal more emphasis has been placed on using 
marginal donor, such as donations after cardiac death (DCDs) and extended criteria 
donors (ECDs) (8-10).   
 
The principle of normothermic perfusion is to maintain an organ in a near to normal 
physiological state by providing the medium for aerobic metabolism to take place. 
This reduces the deleterious effects associated with hypothermic preservation (11-12). 
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In the 1980s, several groups demonstrated an extended preservation time of up to 6 
days for canine kidneys with the adjunctive use of EVNP and hypothermic techniques 
(13-15). The aim of this research was to extend the organ preservation period to 
afford more time for cross-matching and immunological techniques.  However, this 
particular facet is no longer necessary in clinical transplantation, as cross-matching 
technology has advanced and the average cold ischaemic time in the UK for kidney 
transplant is only 16 hours (16).   
 
More recent research has also focussed on using EVNP as a method of resuscitating 
marginal donor kidneys. Experimental studies by Brasile et al demonstrated the 
successful resuscitation of canine kidneys subjected to warm and cold ischaemic 
injury (17).  The findings were corroborated in a porcine model by our group, with the 
demonstration of reversal of some detrimental effects of cold ischaemic injury and 
improved renal blood flow on reperfusion, after only 2 hours of renal normothermic 
perfusion (18).  
 
EVNP up-to-date 
The use of marginal donor kidneys has significantly reduced the donor kidney deficit, 
and globally, an increasing proportion of transplant kidneys are from DCDs and 
ECDs (8,19).  However, the use of marginal donor kidneys is not without risk, and 
has been associated with higher rates of primary non-function, delayed graft function 
(DGF), acute rejection and a greater susceptibility to preservation injury (20-24).   
 
Based on previous experimental work, in 2011 our group (25) reported the first 
clinical case of an ECD donor kidney transplanted into a recipient after a short period 
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of EVNP (35minutes) following nearly 11 hours of cold ischaemia.  The recipient, a 
55-year-old dialysis dependent female had initial slow graft function post-transplant 
but remained dialysis free, and at 4 years follow-up her kidney function has remained 
excellent.  Furthermore, in 2013, we demonstrated the safety and feasibility of EVNP 
in a series of 17 ECD kidneys subjected to 60 minutes of EVNP prior to 
transplantation (26).  The outcomes were compared to a matched cohort of 47 ECD 
kidneys, which had undergone cold storage alone. Although there was a reduced 
incidence of DGF in the EVNP group compared to the control group; 1/17 recipients 
(6%) vs 17/47 (36%), respectively, no difference in graft or patient survival at 12 
months was observed between the two groups.   
 
In 2014, we reported a case of EVNP resuscitation of a pair of human kidneys that 
were originally declined for transplantation due to inadequate in-situ perfusion (27).  
After 60 minutes of EVNP, both kidneys appeared pink, evenly perfused and blood 
flow improved throughout perfusion with a significant amount of urine produced.  
Biopsies taken after EVNP showed some evidence of acute tubular injury, however 
nuclei appeared normal and there was no evidence of cortical necrosis in either 
kidney.  The kidneys were not transplanted but this study demonstrated the potential 
ability of EVNP to resuscitate kidneys declined for reasons such as inadequate 
perfusion. EVNP also allows the assessment of the functional capacity of the kidney 
prior to transplantation. 
 
While these studies demonstrate that EVNP in renal transplantation is both safe and 
feasible as a means for kidney preservation, and may have a role in resuscitating and 
assessing marginal donors kidneys, no long-term data is available yet to fully assess 
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the effects.  Interestingly, rates of DGF in DCDs and ECDs are not associated with 
overall graft survival, unlike donation after brain death (DBDs) (26, 28-29), and it 
will be important to study other long-term data such as graft function and post-
transplant related complications in future studies.   
 
A randomised controlled trial conducted by our group is underway to assess EVNP 
and will recruit 400 patients undergoing a DCD kidney transplant (Maastricht 
Categories III & IV). Patients will be randomly allocated to static cold storage alone 
or in conjunction with 60 minutes of EVNP.  Outcomes will include DGF, short and 
long-term graft function (12 months), graft and patient survival and episodes of acute 
rejection.  The trial will enable a better understanding of the efficacy of EVNP in 
renal transplantation. 
 
Pre transplant assessment using EVNP has major implications for re-evaluating 
discarded organs, and also kidneys from marginal donors.  We have formulated a 
scoring system, which uses several markers of quality assessment: macroscopic 
appearance, perfusion parameters of renal blood flow and urine output of the kidney 
during 60 minutes of EVNP (30).  The scores ranged from 1 (least injured, highest 
quality) to 5 (most injured and lowest-quality).  This scoring system was applied to a 
series of 36 marginal kidneys that underwent EVNP prior to transplantation.  
Recipients with an EVNP assessment score of 3 had a significantly higher rate of 
DGF (38%) compared to those scoring 1 (6%) and 2 (0%).  Post-transplantion 
kidneys with a higher score also had significantly higher serum creatinine levels and a 
lower eGFR at 12 months.  This study demonstrates a promising innovative technique 
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for assessment of marginal kidneys pre-transplant and assessment of their suitability 
for transplantation.   
 
Future of EVNP 
Ex-vivo normothermic perfusion research in heart (31), lung (32) and liver 
transplantation (33-34) has been more expansive than in renal transplantation.  As 
such, we can draw upon this research to facilitate expansion of EVNP in renal 
transplantation. 
 
An appealing quality of EVNP that has attracted a growing amount of research in 
transplant communities, is the principle of administering therapeutic agents solely to 
the organ pre-transplantation, allowing direct manipulation.  This also avoids 
unwanted systemic effects from administering these agents to the patient and obviates 
problems with targeting particular organ cells.  The applications of such could include 
use of stem cell and gene therapy to target complex transplantation issues such as 
rejection and fibrosis.    
 
Using human kidneys, Brasile et al demonstrated effective transfection of a 
recombinant adenovirus with an encoded GFP reporter protein delivered during 
EVNP (35).  Localisation of the reporter gene to the intimal layer of blood vessels 
demonstrated the ability to target a specified delivery site.  Furthermore, using gene-
silencing techniques our group demonstrated a reduction in expression of caspase-3 
(36).  Caspase-3 is a pro-apoptotic protein that is upregulated in ischaemic-
reperfusion injury, and after addition of caspase-3 specific small interfering RNA into 
the cold preservation solution for 24hours, the porcine kidneys showed decreased 
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caspase-3 expression level.  Treated kidneys demonstrated better renal oxygenation 
and acid-balance homeostasis in comparison to the control group.  Although 
combining EVNP with this technique may be more efficacious, it is likely that 
prolonged periods of EVNP will be required for effective manipulation of the kidney 
before transplantation.  Nonetheless, the research to date paves the way for 
investigating gene therapy in EVNP. 
 
Recent experimental work by McConnell et al (37) used a novel silicon microparticle 
and viral nanoparticle hybrid model, as a means of a delivery platform.  They were 
able to demonstrate successful uptake and gene delivery in endothelial cells during 
EVNP in a porcine lung transplantation model.  The inherent mechanisms for 
endosomal escape and nuclear localisation make the use of viral-associated 
nanoparticles an effective gene-delivery platform, whilst the microparticle enabled a 
high quantity of nanoparticles (up to 1,000) to be attached, thereby exponentially 
increasing the impact of the therapy per microparticle uptake into cells.  Although 
much more research is required to determine mechanistic processes of uptake and 
downstream processes of gene expression, this holds an exciting prospect for effective 
targeting of cells within a heterogeneous cellular environment.  In collaboration with 
Yale University, preliminary work is underway by our group to assess the uptake of 
endothelium targeted nanoparticles using EVNP in declined human kidneys.  
 
Another growing area of interest in transplantation is the use of mesenchymal stem 
cells (MSCs).  Although stem cells are notable for their differentiation properties, 
which modulate tissue repair and regeneration (38), their immunomodulatory and 
paracrine properties, such as anti-apoptotic and anti-fibrotic effects make them 
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attractive in the transplant setting.  Experimental studies using different models of 
kidney injury with MSCs have demonstrated amelioration in renal function following 
ischaemia-reperfusion injury, reduced tubular injury and prolonged survival (39-42).   
Currently, a phase I clinical trial is underway assessing the use of multipotent adult 
progenitor cells (MAPCs) in liver transplantation (43).  Recipients will be 
administered MAPCs day 1 and 3 post-transplantation and it is postulated that these 
MAPCs may reduce the dose of immunosuppressive therapy required. 
 
To our knowledge only one study has combined the use of MSCs and ex-vivo 
perfusion.  Lee et al (44) demonstrated attenuation of E. Coli endotoxin induced -
acute lung injury after addition of allogenic human MSCs during EVNP of a human 
lung.  Specifically, alveolar epithelial fluid transport mechanisms were restored with 
reduction in pulmonary oedema injury.  Early research using MSCs is promising and 
warrants further work to delineate their role and function in renal transplantation.  
EVNP provides an ideal route for such therapies because not only does it allow direct 
targeting of the organ of interest, bypassing undesirable systemic effects, but also the 
organ is in a functioning state whilst receiving the therapy. This allows the effects to 
be closely monitored and the mechanisms and therapeutic actions of these agents to 
be studied in isolation. 
 
Conclusion 
To date, ex-vivo normothermic kidney perfusion has been translated from 
experimental models through to clinical practice. EVNP has exciting and promising 
prospects for the future of clinical renal transplantation.  It is a safe and feasible 
alternative organ preservation technique, which can be used in conjunction with 
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hypothermic preservation techniques. It is particularly apt for marginal donor kidneys 
providing an innovative way of assessing quality of organs pre-transplant and 
improve their quality. EVNP can also be used to ensure that we maximise the use of 
all available donor organs and reduce the number of organ that are discarded. Stem 
cell and gene therapies have demonstrated the ability to facilitate organ repair and 
immunomodulation. The administration of such therapies directly to the kidney using 
EVNP is a novel and exciting application in renal transplantation. 
 12 
 
Key Points 
1. EVNP is a safe and feasible alternative method of organ preservation in renal 
transplantation that may be more beneficial in marginal donor kidneys. 
2. EVNP has the potential to resuscitate kidneys, particularly from marginal donors 
and provides an innovate means of quality assessment of the organ pre-transplant. 
3. The future of EVNP research includes gene and stem cell therapy, which have 
demonstrated organ repair and immunomodulation. 
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